Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancerExamines specific targets and the cognate drugsEvaluates molecular modes of innate and evolving resistance weiterlesen